- Advertisement -

A new study shows that the Pfizer-BioNTech vaccine is 90% effective in preventing COVID-19 hospitalizations for up to six months after thorough vaccination, even with the more transmissible delta variant And even without the booster shot.


But the same study reported that the effectiveness of the vaccine goes down when it comes to acquiring COVID-19 infection. Specifically, according to the study, effectiveness was measured at 47% five months after people who received the two-dose vaccine.

- Advertisement -

Pfizer-funded study was published In “The Lancetta”“Monday. From December 2020 to August 2021, researchers studied and analyzed the health records of more than 3.4 million people 12 years of age and older in Kaiser Permanente Southern California who were fully vaccinated with the Pfizer-BioEntech vaccine had gone.

related: Pfizer vaccine 88% effective against delta variant, study finds

“Our results replicate in a real-world US setting that vaccination with BNT162b2” [Pfizer-BioNTech vaccine] remains an essential tool to prevent COVID-19, especially hospital admissions associated with COVID-19, due to all existing forms of anxiety,” the study authors said.

The researchers said they conducted the study to see how the Pfizer-BioNTech vaccine is holding up against multiple circulating COVID-19 variants.

related: Cominternity: Pfizer-BioNtech explain the meaning of the name of the COVID-19 vaccine

Pfizer-BioNtech started mentioning its COVID-19 vaccine by whom? Its brand name is Comirnaty After the US Food and Drug Administration gave its full approval to the shot in August. The proposed common name for the comirnaty is tozinameran.

In September, the US Food and Drug Administration Third booster shot of vaccine authorized For Americans who are 65 and older, young adults with underlying health conditions and in jobs that put them at higher risk for COVID-19. Under FDA authorization, vaccinated Americans are eligible for a third dose six months after receiving their second Pfizer shot.

related: FDA approves Pfizer booster for those 65 and older, others at higher risk

The FDA is convening its external panel of advisors next week to review booster data for both Johnson & Johnson and Moderna and their vaccines.

According to U.S. Centers for Disease Control and Prevention, 65.5% of Americans age 12 and older are fully vaccinated. An estimated 70 million eligible Americans who have not been vaccinated provide Kindling for the Delta version.

The US reached its latest heartbreaking pandemic milestone last week, killing 700,000 people from COVID-19, just as the surge from the delta version has begun to slow and provide some relief to overwhelmed hospitals.

Nationwide, the number of people now in hospital with COVID-19 has fallen to nearly 75,000, up from more than 93,000 in early September. New cases are falling on average by about 112,000 per day, a drop of about one-third over the past 2 1/2 weeks.

related: US COVID-19 deaths top 700,000 as Delta variant fuels pandemic

Deaths also appear to be declining, with an average of about 1,900 per day compared to more than 2,000 a week ago.

The easing of the summer boom has been attributed to more mask wear and more people getting vaccinated. The reduction in the number of cases could also be due to the virus burning through susceptible people and running out of fuel in some places.

But health officials and hospitals are prepared for another potential surge in the winter months.

The government’s top infectious disease expert Dr. Anthony Fauci warned Friday that some may see encouraging trends as a reason to go without vaccination.

“It’s good news that we are starting to see curves”, he said. “This is not an excuse to shy away from the issue of needing vaccinations.”

This story was reported from Los Angeles.